Author:
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 253 | 149 | 7 |
| Full Text Views | 8 | 0 | 0 |
| PDF Downloads | 8 | 0 | 0 |
Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
P E Thuma
P E Thuma
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by P E Thuma in
Current site
Google Scholar
PubMed
Search for other papers by P E Thuma in
Current site
Google Scholar
PubMed
N F Olivieri
N F Olivieri
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by N F Olivieri in
Current site
Google Scholar
PubMed
Search for other papers by N F Olivieri in
Current site
Google Scholar
PubMed
G F Mabeza
G F Mabeza
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by G F Mabeza in
Current site
Google Scholar
PubMed
Search for other papers by G F Mabeza in
Current site
Google Scholar
PubMed
G Biemba
G Biemba
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by G Biemba in
Current site
Google Scholar
PubMed
Search for other papers by G Biemba in
Current site
Google Scholar
PubMed
D Parry
D Parry
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by D Parry in
Current site
Google Scholar
PubMed
Search for other papers by D Parry in
Current site
Google Scholar
PubMed
S Zulu
S Zulu
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by S Zulu in
Current site
Google Scholar
PubMed
Search for other papers by S Zulu in
Current site
Google Scholar
PubMed
F F Fassos
F F Fassos
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by F F Fassos in
Current site
Google Scholar
PubMed
Search for other papers by F F Fassos in
Current site
Google Scholar
PubMed
R A McClelland
R A McClelland
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by R A McClelland in
Current site
Google Scholar
PubMed
Search for other papers by R A McClelland in
Current site
Google Scholar
PubMed
G Koren
G Koren
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by G Koren in
Current site
Google Scholar
PubMed
Search for other papers by G Koren in
Current site
Google Scholar
PubMed
G M Brittenham
G M Brittenham
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by G M Brittenham in
Current site
Google Scholar
PubMed
Search for other papers by G M Brittenham in
Current site
Google Scholar
PubMed
V R Gordeuk
V R Gordeuk
Pennsylvania State University Hershey Medical Center, USA.
Search for other papers by V R Gordeuk in
Current site
Google Scholar
PubMed
Search for other papers by V R Gordeuk in
Current site
Google Scholar
PubMed
While the parenteral iron-chelating agent desferrioxamine B has anti-malarial activity in humans, the usefulness of an orally active chelator for this indication has not been investigated previously in vivo. We conducted a prospective, double-blind, placebo-controlled, cross-over trial of deferiprone (L1; CP20; 1,2-dimethyl-3-hydroxypyridin-4-one) in 25 adult Zambians with asymptomatic Plasmodium falciparum parasitemia. Deferiprone was administered daily for three or four days in divided doses of 75 or 100 mg/kg of body weight, dosages that are effective for treating iron overload. No reduction in asexual intra-erythrocytic parasites was observed during or after deferiprone treatment. The mean peak plasma concentration of deferiprone (108.9 +/- 24.9 micromol/L) achieved was within the range demonstrated to inhibit the growth of P. falciparum in vitro, but the systemic exposure as determined by the 24-hr plasma concentration-time curve would not be predicted inhibit growth in vivo. No evidence of deferiprone-associated hematological toxicity was noted in this short-term study of these subjects, all of whom had clinical evidence of normal body iron stores. Because of the risk of neutropenia and other adverse effects with higher doses or prolonged use of the chelator, additional trials of deferiprone as a sole anti-malarial agent would not seem to be justified. In contrast, further efforts are needed to develop other orally active iron-chelating agents specifically for their anti-malarial action.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 253 | 149 | 7 |
| Full Text Views | 8 | 0 | 0 |
| PDF Downloads | 8 | 0 | 0 |